Expect MoRe®
Do MoRe®
Careers
Work With MiRus
At MiRus we give you the opportunity to develop your career based on your strengths and potential. MiRus is an early stage company with deep proprietary technology in both implants and surgical navigation. MiRus was started by a team of experienced entrepreneurs with a history of creating disruptive technologies and very successful, highly valued companies.
CAREERS
Open Positions
MiRus® Announces Launch of Molybdenum-Rhenium Low Profile ATLAS™ MoRe® Foot and Ankle Plating System
ATLANTA — September 18, 2023— MiRus announces limited market release in the U.S. of its ATLAS™ MoRe® Foot and Ankle Plating System, the thinnest foot and ankle plate on the market for treatment of foot and ankle conditions. The molybdenum-rhenium alloy used in the plates allows for a dramatically smaller footprint of 1.0mm thickness without […]
Read MoreMiRus® Receives FDA 510(k) Clearance forCYGNUS MoRe® Anterior Cervical Plate ATLANTA — August 15, 2022— MiRus announced today that it has received FDA 510(k) clearance of the CYGNUS MoRe® Anterior Cervical Plate System, the narrowest and thinnest cervical plate on the market. The molybdenum-rhenium alloy used in the plate allows for a dramatically smaller […]
Read MoreMiRus is setting the pace as one of the fastest-growing companies in the metro Atlanta area with over 250% growth in the past two years ! Atlanta Business Chronicle 2022 Pacesetter Award ow.ly/Jy6a50IXUVZ
Read MoreMiRus announces plans for site of new headquarters with the purchase of the Franklin Gateway 6.72 acre property from the City of Marietta. The new headquarters will be a three-story facility comprising over 70,000 square feet. https://www.mariettaga.gov/CivicAlerts.aspx?AID=3474
Read MoreATLANTA- August 31, 2021 – MiRus LLC, the leading innovator in rhenium-based superalloy medical implants announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its IO™ Expandable Lumbar Interbody. The IO™ Expandable Lumbar Interbody can be utilized in both PLIF and TLIF procedures. It features the lowest insertion profile […]
Read MoreATLANTA- July 27, 2021 – MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®). The round was led by Mammoth Scientific and multi-generational family offices who have supported […]
Read More“The best things in life are somewhat accidental,” says Dr. Jay Yadav. He should know. From aspiring to study astronomy to choosing medicine to work on cancer and then opting for cardiology and then innovating cardiovascular medical devices to save lives which led to being a serial entrepreneur, Dr. Yadav admits his path of success is a summation of “serendipitous” happenings in his life and his spontaneous reactions to these situations. In fact, the trend seems to have applied to the way he met his better-half, Marshalla, he says “I only met her one time at the hospital when I was a resident at Duke. Our paths may never have crossed again if I had not immediately asked her to have dinner.”
Read MoreMammoth™ Scientific, a health science and technology venture capital firm, announced the launch of a $100 million venture capital fund today. Co-founders Dr. Jay Yadav, Tommy Martin, Kim Mackrill, Dr. Matthew McGirt and Jud Mackrill provide venture capital for health science and technology companies who are maturing beyond seed rounds “As veterans in the startup world, we have first-hand knowledge of the […]
Read MoreMiRus announced today that they will offer a LIFETIME LIMITED WARRANTY on its Molybdenum-Rhenium ( MoRe®) superalloy rod technology. The warranty will cover full replacement of the MoRe® Rod and corresponding MiRus hardware used in spinal fusion cases should the MoRe® Rod fracture. The warranty will cover all thoracolumbar MoRe® rods implanted as part of the EUROPA™ Pedicle Screw System supplied by MiRus in the United States effective March 1, 2021.
Read More